U.S. patent application number 17/064215 was filed with the patent office on 2021-05-20 for prophylactic protection against viral infections, particularly hiv.
This patent application is currently assigned to ORGENESIS INC.. The applicant listed for this patent is ORGENESIS INC.. Invention is credited to Tom HODGE, David SIDRANSKY, Luis SQUlQUERA, Jamie SULLEY.
Application Number | 20210145960 17/064215 |
Document ID | / |
Family ID | 1000005134981 |
Filed Date | 2021-05-20 |
![](/patent/app/20210145960/US20210145960A1-20210520-D00000.png)
![](/patent/app/20210145960/US20210145960A1-20210520-D00001.png)
![](/patent/app/20210145960/US20210145960A1-20210520-D00002.png)
United States Patent
Application |
20210145960 |
Kind Code |
A1 |
SULLEY; Jamie ; et
al. |
May 20, 2021 |
PROPHYLACTIC PROTECTION AGAINST VIRAL INFECTIONS, PARTICULARLY
HIV
Abstract
An experiment has shown that ranpirnase is a microbicide. It is
believed that topical application of a topical pharmaceutical
composition consisting essentially of a prophylactically effective
concentration of an enzymatically-active ribonuclease (e.g.
ranpirnase) and a viscous vehicle that does not unacceptably
interfere with the enzymatic activity (e.g. K-Y.RTM. Brand Jelly)
will prophylactically protect an individual from a
sexually-transmitted viral infection, particularly HIV. It is also
believed that e.g. ranpirnase can be delivered to tissues of an
individual who is to be prophylactically protected against viral
infections by transfecting ranpirnase DNA into human microbiota and
exposing the individual to the thus-modified human microbiota. It
is also believed that ranpirnase can be delivered to a woman who is
to be prophylactically protected against a sexually-transmitted
viral infection by use of an intravaginal ring that has been
impregnated with ranpirnase.
Inventors: |
SULLEY; Jamie; (La Jolla,
CA) ; SQUlQUERA; Luis; (Buenos Aires, AR) ;
SIDRANSKY; David; (Pikesville, MD) ; HODGE; Tom;
(Athens, GA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ORGENESIS INC. |
Germantown |
MD |
US |
|
|
Assignee: |
ORGENESIS INC.
Germantown
MD
|
Family ID: |
1000005134981 |
Appl. No.: |
17/064215 |
Filed: |
October 6, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15582133 |
Apr 28, 2017 |
10835598 |
|
|
17064215 |
|
|
|
|
14793920 |
Jul 8, 2015 |
9642794 |
|
|
15582133 |
|
|
|
|
14462520 |
Aug 18, 2014 |
|
|
|
14793920 |
|
|
|
|
62367050 |
Jul 26, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 2039/525 20130101;
C07K 14/16 20130101; C12N 15/86 20130101; A61K 39/21 20130101; A61K
39/00 20130101; C12Y 301/27005 20130101; C12N 2740/16043 20130101;
A61K 38/465 20130101; A61K 35/744 20130101; C07K 7/08 20130101;
C12N 9/22 20130101; A61K 35/747 20130101; C12N 2740/16334 20130101;
C12Y 301/27 20130101; A61K 9/0034 20130101; A61K 9/0014 20130101;
A61K 2039/53 20130101; A61K 48/00 20130101; A61K 38/00
20130101 |
International
Class: |
A61K 39/21 20060101
A61K039/21; C07K 14/16 20060101 C07K014/16; C07K 7/08 20060101
C07K007/08; C12N 15/86 20060101 C12N015/86; A61K 38/46 20060101
A61K038/46; A61K 9/00 20060101 A61K009/00; A61K 35/744 20060101
A61K035/744; A61K 35/747 20060101 A61K035/747; C12N 9/22 20060101
C12N009/22 |
Claims
1. A method of prophylactically protecting an individual from
transmission of a sexually-transmitted infection, comprising the
step of topically applying to the individual a topical
pharmaceutical composition consisting essentially of a
prophylactically effective concentration of an enzymatically-active
ribonuclease and a viscous vehicle that does not unacceptably
interfere with the enzymatic activity, wherein the infection is
Human Papilloma Virus (HPV) or Herpesviridae.
2. The method of claim 1, wherein the infection is HPV
infection.
3. The method of claim 2, wherein the infection is selected from
the group consisting of anogenital warts, epidermodysplasia
verrucciformis, Buschke-Lowenstein disease, Bowenoid papulosis, and
dysplasia.
4. The method of claim 1, wherein the infection is Herpesviridae
infection.
5. The method of claim 1, wherein the enzymatically-active
ribonuclease is a member of the ribonuclease A superfamily.
6. The method of claim 5, wherein the enzymatically-active
ribonuclease is selected from the group consisting of ranpirnase
and the '805 ranpirnase variant.
7. The method of claim 6, wherein the enzymatically-active
ribonuclease is ranpirnase.
8. The method of claim 5, wherein the enzymatically-active
ribonuclease is selected from the group consisting of Amphinase 2
and rAmphinase 2.
9. The method of claim 1, wherein the vehicle is an aqueous
vehicle.
10. The method of claim 9, wherein the vehicle is a gel, a serum,
or a lotion.
11. The method of claim 9, wherein the vehicle is an approved
sexual lubricant.
12. The method of claim 1, wherein the vehicle is compatible with
latex condoms.
13. The method of claim 1, wherein the pharmaceutical contains
between 0.06 and 66 .mu.g of enzymatically-active ribonuclease per
ml of vehicle.
14. The method of claim 13, wherein the pharmaceutical contains
between 6 and 66 .mu.g of enzymatically-active ribonuclease per ml
of vehicle.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation application of U.S. patent
application Ser. No. 15/582,133 filed Apr. 28, 2017, which claims
priority to U.S. Provisional application No. 62/367,050 filed Jul.
26, 2016. This application is also a continuation-in-part of
application Ser. No. 14/793,920, filed Jul. 8, 2015, which is a
continuation-in-part of application Ser. No. 14/462,520, filed Aug.
18, 2014. The entire disclosure of these applications are hereby
expressly incorporated herein by reference for all purposes.
CROSS-REFERENCE TO SEQUENCE LISTING
[0002] The contents of the text file submitted electronically
herewith are incorporated herein by reference in their entirety: A
computer readable format copy of the Sequence Listing (filename:
TAMI_014_02US_SeqList_ST25.txt, date recorded: Apr. 28, 2017, file
size 4 kilobytes).
BACKGROUND OF THE INVENTION
[0003] The disclosure relates to prophylactic protection against
viral infections, and more particularly relates to antiviral
prophylactic protection that requires neither injection nor oral
administration of a prophylactic agent. In its most immediate
sense, the invention relates to use of an enzymatically-active
ribonuclease, and particularly use of ranpirnase, to
prophylactically protect an individual from viral infections such
as human immunodeficiency virus ("HIV").
[0004] Sexually transmitted infections, and particularly HIV, pose
a significant public health threat. At present, individuals wishing
to protect themselves against such infections must rely upon
mechanical measures (such as condoms and dental dams) that prevent
them from coming into contact with their partner's bodily fluids,
which may contain HIV. These measures are non-optimal because some
individuals are reluctant to use them. More recently, the use of
orally administered antiretrovirals (e.g. tenofovir) has been
postulated as pre-exposure prophylactic treatment. While oral
prophylaxis is effective, it suffers from significant
disadvantages. Oral prophylaxis must be used consistently for a
prolonged period and its effectiveness is reduced or even
eliminated if the patient is not fully compliant. Other oral
medications can adversely affect the efficacy of oral prophylaxis.
And, the effectiveness of an orally administered drug can be
seriously compromised if a patient suffers from nausea or from
diarrhea.
[0005] It would be advantageous to provide prophylaxis against
sexually transmitted infections, and more particularly against HIV,
that did not require the use of mechanical measures such as condoms
and dental dams and that did not need to be administered orally or
by injection.
DETAILED DESCRIPTION
[0006] It is known that ranpirnase is active against HIV. However,
an experiment has shown something unexpected, namely, that
topically-applied ranpirnase acts as a microbicide, i.e. that
ranpirnase can prevent cells from becoming infected with HIV. In
this experiment, rectal tissue biopsies taken from HIV-uninfected
individuals were incubated in solutions containing a mixture of
ranpirnase and HIV. The explanted tissues were then cultured and
supernatant was collected at intervals. The supernatant was assayed
to quantify the amount of p24 antigen and to thereby determine the
severity with which the tissues were infected with HIV.
[0007] The assays showed that severity of HIV infection in the
tissues was affected by the concentration of ranpirnase in the
solution. As ranpirnase concentration increased, the level of HIV
in the supernatant decreased. Hence, this experiment demonstrated
that ranpirnase had a prophylactic effect on the explanted tissues;
exposing the tissues to ranpirnase diminished the susceptibility of
the tissues to HIV infection in a dose-dependent manner.
[0008] This experiment is strong evidence that an individual can be
prophylactically protected from viral sexually transmitted diseases
such as HIV by applying ranpirnase topically to body regions (e.g.
genitalia, rectum, mouth) that might be exposed to HIV during
sexual intercourse, prior to (or even during) sexual
intercourse.
[0009] The above-referenced parent patent application discloses a
topical pharmaceutical composition consisting essentially of a
therapeutically effective amount of an enzymatically-active
ribonuclease and a viscous vehicle that does not unacceptably
interfere with the enzymatic activity, wherein the vehicle is
selected from the group consisting of a gel, a serum, or a lotion.
Advantageously, the ribonuclease is ranpirnase and the vehicle is
K-Y.RTM. Brand Jelly.
[0010] This topical pharmaceutical composition is particularly
well-suited for prophylactic application of ranpirnase (or another
enzymatically-active ribonuclease) because the vehicle does not
unacceptably interfere with the enzymatic activity of the
ribonuclease and the viscosity of the vehicle allows the
composition to remain where it has been applied so that the active
pharmaceutical ingredient (e.g. ranpirnase)--does not run off.
[0011] However, it is believed that topical application of
ranpirnase is not the only way to administer it for prophylactic
protection. It is also believed possible to protect an individual
against a virus by infecting the individual with human microbiota
into which ranpirnase DNA has been transfected, or by dispensing
the ranpirnase using an intravaginal ring.
[0012] Although this experiment was only carried out using
ranpirnase, there is at least one other ribonuclease (identified
below) that is highly homologous to ranpirnase and that has similar
antiviral activities. For reasons set forth below, it is believed
that any such ribonuclease will be a microbicide and will have
similar prophylactic effects.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] The invention will be better understood with reference to
the exemplary and non-limiting drawings, in which:
[0014] FIG. 1 graphs the cumulative HIV infection of 15 individual
rectal tissue biopsies in the herein-described experiment as a
function of ranpirnase concentration;
[0015] FIG. 2 graphs the cumulative averaged HIV infection of 5
rectal tissue biopsy triplets in the herein-described experiment as
a function of ranpirnase concentration;
[0016] FIG. 3 graphs the data graphed in FIG. 2 in a different
format to clearly show the standard error of the mean at each
ranpirnase concentration; and
[0017] FIG. 4 shows a vaginal ring such as would be used in a third
embodiment of the invention.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[0018] Ranpirnase is a proteinaceous enzymatically-active
ribonuclease having the amino acid sequence of SEQ ID NO:1,
previously disclosed and claimed in U.S. Pat. No. 5,559,212.
[0019] An experiment was carried out using rectal tissue biopsies
taken from six healthy HIV-uninfected volunteers. Three tissue
explants were taken from each volunteer.
[0020] Five liquid mixtures were formulated to test the
prophylactic effect of ranpirnase against HIV. The mixtures
were
[0021] 10.sup.5 TCID.sub.50 of HIV-1.sub.BaL together with 0.06
.mu.g/mL ranpirnase
[0022] 10.sup.5 TCID.sub.50 of HIV-1.sub.BaL together with 0.6
.mu.g/mL ranpirnase
[0023] 10.sup.5 TCID.sub.50 of HIV-1.sub.BaL together with 6
.mu.g/mL ranpirnase
[0024] 10.sup.5 TCID.sub.50 of HIV-1.sub.BaL together with 66
.mu.g/mL ranpirnase
[0025] together with a control:
[0026] 10.sup.5 TCID.sub.50 of HIV-1.sub.BaL together with 0.00
.mu.g/mL ranpirnase
[0027] The fifteen tissue explants were arranged into five groups
of three, with each group of three being incubated for two hours in
a single one of these mixtures (one group is incubated in the
control). The tissue explants were then washed multiple times and
cultured at 37.degree. C. and 5% CO.sub.2 for fourteen days, during
which interval supernatant was collected on Days 3, 7, 10, and 14.
The culture medium was made up of equal parts of complete RMPI and
Zosyn.RTM. 50 mg/mL, with 500 mL of complete RMPI being made up of
[0028] 90% RPMI 1640--445 mL, [0029] 10% Fetal Bovine Serum--50 mL,
and [0030] 1% Antibiotic/Antimycotic--5.0 mL.
[0031] The severity of HIV infection of the tissue explants was
determined by assaying the supernatant for HIV-1 p24 antigen using
the AlphaLISA platform. The efficacy endpoint was the tissue
explant weight adjusted Day 14 cumulative HIV-1 p24. As can be seen
in all the Figures, increasing concentration of ranpirnase caused a
dose-dependent reduction in HIV-1 p24 antigen in the tissue
explants. The statistical significance p of the displayed data is
shown in the Figures; whether the data are averaged or not, the
results for 0.00 .mu.g/mL, 0.06 .mu.g/mL, and 0.6 .mu.g/mL
concentrations of ranpirnase are below the 5% level of
significance. And, the results for 6.00 .mu.g/mL and 66 .mu.g/mL
concentrations of ranpirnase are below the 1% level of significance
where the results of each group of three tissue explants are
averaged, and below the 0.1% level of significance where the
results of each tissue explant is taken individually.
[0032] In each of the Figures, the standard error of the mean is
also shown by the vertical lines shown by themselves in FIG. 3 and
superposed on the bars in FIGS. 1 and 2. As would be expected, in
instances wherein the level of significance is highly stringent
(less than 1%) the standard error of the mean is smaller than in
instances wherein the level of significance is less stringent (less
than 5%).
[0033] It will be noted that this experiment was conducted using
tissue explants from six individuals even though only five triplets
of tissue explants were assayed after exposure to the identified
mixtures of ranpirnase and HIV-1.sub.BaL and the control. This is
because an additional triplet of tissue explants exposed to
ranpirnase alone was subjected to an MTT assay in order to rule out
the possibility that ranpirnase caused cellular toxicity.
[0034] Hence, this experiment showed that tissue explants exposed
to ranpirnase--and particularly to ranpirnase concentrations of 6
.mu.g/mL and greater--developed increased resistance to HIV
infection, i.e. that ranpirnase had a microbicidal effect.
[0035] Advantageously, the topical pharmaceutical composition
disclosed in the above-referenced parent patent application is used
as a microbicide, and is topically applied to an individual who is
to be protected. Further advantageously, the topical pharmaceutical
composition can be applied to body regions that might be exposed to
HIV during sexual intercourse The enzymatically-active ribonuclease
can be ranpirnase. Alternatively, there is at least one other
ribonuclease having enzymatic activities similar to that of
ranpirnase, and this may be used instead of ranpirnase. For
example, the "805 variant" (SEQ ID NO:2)is over 90% homologous to
ranpirnase, in that the amino acid sequences of the two
ribonucleases differ at only three positions (positions 11, 20, and
103) and has similar antiviral activities. Furthermore, it is known
that the active site of ranpirnase is located at its N-terminal,
and since the N-terminal amino acid sequences of ranpirnase and the
'805 variant are identical, it follows that they will encode
identical active sites. Thus, a person of ordinary skill in this
art would expect the '805 variant to have the same prophylactic
effect as ranpirnase has.
[0036] Although this experiment was carried out by exposing rectal
tissue explants to solutions containing ranpirnase, it is believed
that the same results would be achieved by using another method to
deliver ranpirnase to the tissue that may be exposed to HIV. This
other method, a second preferred embodiment of the invention, is by
using human microbiota to produce ranpirnase. An example of this
mode of administration can be found at Gebhart et al., mBio, Vol.
6, Issue 2, pp. 1-13, (March/April 2015). The disclosure of this
publication is incorporated herein by reference.
[0037] For example, let it be assumed that mucosal tissues (e.g.
the vagina, the rectum) are to be prophylactically protected from
HIV. E. coli and Lactobacillus are part of the microbiota in those
regions. Ranpirnase DNA can be transfected into E. coli or
Lactobacillus (or both) and the thus-modified E. coli or
Lactobacillus introduced into the subject. The modified E. coli or
Lactobacillus would then infect the subject and thereby produce
ranpirnase in the mucosal tissues involved. Alternatively, other
bacteria could be used to prophylactically protect other tissues
against other viral infections. For example, probiotic E. coli into
which ranpirnase DNA had been transfected could be used to protect
against viral infections of the digestive tract. Similarly-modified
saprophytic Streptococcus could be delivered to protect a subject's
external genitalia against HIV.
[0038] A third preferred embodiment of the invention is suitable
for use by women. In this third embodiment, an intravaginal ring 10
(FIG. 4) of a suitably porous and biocompatible material (such as
is described below) is impregnated with ranpirnase and inserted
into the vagina, where the ranpirnase is dispensed. The ranpirnase
may be mixed with other agents (e.g. dispersing agents).
[0039] Intravaginal rings are known and are used to dispense birth
control drugs as well as dapivirine (a candidate microbicide now in
clinical trials). An exemplary composition of such a ring is
disclosed at Table 2 of Holt, et al., Antimicrobial Agents and
Chemotherapy, Vol. 59, No. 7, pp. 3761-3770 (July, 2015), the
disclosure of which is incorporated herein by reference.
[0040] Although preferred embodiments have been described above,
the invention is limited only by the following claims:
Sequence CWU 1
1
41104PRTRana pipiens 1Glu Asp Trp Leu Thr Phe Gln Lys Lys His Ile
Thr Asn Thr Arg Asp1 5 10 15Val Asp Cys Asp Asn Ile Met Ser Thr Asn
Leu Phe His Cys Lys Asp 20 25 30Lys Asn Thr Phe Ile Tyr Ser Ala Pro
Glu Pro Val Lys Ala Ile Cys 35 40 45Lys Gly Ile Ile Ala Ser Lys Asn
Val Leu Thr Thr Ser Glu Phe Tyr 50 55 60Leu Ser Asp Cys Asn Val Thr
Ser Arg Pro Cys Lys Tyr Lys Leu Lys65 70 75 80Lys Ser Thr Asn Lys
Phe Cys Val Thr Cys Glu Asn Gln Ala Pro Val 85 90 95His Phe Val Gly
Val Gly Ser Cys 1002104PRTRana pipiens 2Glu Asp Trp Leu Thr Phe Gln
Lys Lys His Val Thr Asn Thr Arg Asp1 5 10 15Val Asp Cys Asn Asn Ile
Met Ser Thr Asn Leu Phe His Cys Lys Asp 20 25 30Lys Asn Thr Phe Ile
Tyr Ser Arg Pro Glu Pro Val Lys Ala Ile Cys 35 40 45Lys Gly Ile Ile
Ala Ser Lys Asn Val Leu Thr Thr Ser Glu Phe Tyr 50 55 60Leu Ser Asp
Cys Asn Val Thr Ser Arg Pro Cys Lys Tyr Lys Leu Lys65 70 75 80Lys
Ser Thr Asn Lys Phe Cys Val Thr Cys Glu Asn Gln Ala Pro Val 85 90
95His Phe Val Gly Val Gly Arg Cys 1003114PRTRana pipiens 3Lys Pro
Lys Glu Asp Arg Glu Trp Glu Lys Phe Lys Thr Lys His Ile1 5 10 15Thr
Ser Gln Ser Val Ala Asp Phe Asn Cys Asn Arg Thr Met Asn Asp 20 25
30Pro Ala Tyr Thr Pro Asp Gly Gln Cys Lys Pro Ile Asn Thr Phe Ile
35 40 45His Ser Thr Thr Gly Pro Val Lys Glu Ile Cys Arg Arg Ala Thr
Gly 50 55 60Arg Val Asn Lys Ser Ser Thr Gln Gln Phe Thr Leu Thr Thr
Cys Lys65 70 75 80Asn Pro Ile Arg Cys Lys Tyr Ser Gln Ser Asn Thr
Thr Asn Phe Ile 85 90 95Cys Ile Thr Cys Arg Asp Asn Tyr Pro Val His
Phe Val Lys Thr Gly 100 105 110Lys Cys4115PRTRana pipiens 4Met Lys
Pro Lys Glu Asp Arg Glu Trp Glu Lys Phe Lys Thr Lys His1 5 10 15Ile
Thr Ser Gln Ser Val Ala Asp Phe Asn Cys Asn Arg Thr Met Asn 20 25
30Asp Pro Ala Tyr Thr Pro Asp Gly Gln Cys Lys Pro Ile Asn Thr Phe
35 40 45Ile His Ser Thr Thr Gly Pro Val Lys Glu Ile Cys Arg Arg Ala
Thr 50 55 60Gly Arg Val Asn Lys Ser Ser Thr Gln Gln Phe Thr Leu Thr
Thr Cys65 70 75 80Lys Asn Pro Ile Arg Cys Lys Tyr Ser Gln Ser Asn
Thr Thr Asn Phe 85 90 95Ile Cys Ile Thr Cys Arg Asp Asn Tyr Pro Val
His Phe Val Lys Thr 100 105 110Gly Lys Cys 115
* * * * *